Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sanofi (OtherSNYNF)

Tipranks - Sat Apr 11, 3:52AM CDT

Analysts fell to the sidelines weighing in on Pfizer (PFE) and Sanofi (SNYNF) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Easter Sale - 70% Off TipRanks

Pfizer (PFE)

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. The company’s shares closed last Thursday at $27.22.

According to TipRanks.com, Schott is a 4-star analyst with an average return of 5.1% and a 56.0% success rate. Schott covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, Bristol-Myers Squibb, and Elanco Animal Health. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $28.97 average price target, which is a 6.5% upside from current levels. In a report issued on March 30, Bernstein also maintained a Hold rating on the stock with a $30.00 price target.

See the top stocks recommended by analysts >>

Sanofi (SNYNF)

UBS analyst Matthew Weston maintained a Hold rating on Sanofi today and set a price target of EUR88.00. The company’s shares closed last Thursday at $93.85, close to its 52-week low of $88.90.

According to TipRanks.com, Weston is ranked #1710 out of 12128 analysts.

Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $109.38, which is a 16.5% upside from current levels. In a report issued on March 30, J.P. Morgan also maintained a Hold rating on the stock with a EUR95.00 price target.

Read More on PFE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.